NeuBase Therapeutics Inc expected to post a loss of 23  cents a share - Earnings Preview

NeuBase Therapeutics

07/02/2022 11:06

* NeuBase Therapeutics Inc  NBSE.OQ   NBSE.O  is expected
to show
no change in quarterly revenue when it reports  results on
February 9 (estimated). 
    * ​Refinitiv's mean analyst estimate for NeuBase
Therapeutics Inc
is for a loss of 23 cents per share. For the same quarter last
year, the company reported a loss of 18 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NeuBase
Therapeutics Inc is $16​, about 90.6% above​ its last closing
price of $1.50. ​​​
    * 

This summary was machine generated February 7 at 11:06 GMT.  All
figures in US dollars  unless otherwise stated